GlassScriptPhysician profile
Garima Narayen
NPI 1285053926
$4,278.08
in general payments reported to CMS, 2019-2025
16 companies · $506 in 2025
The $506 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $243 · 2021: $851 · 2022: $1,002 · 2023: $953 · 2024: $724 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $638.16 | 2020-2023 | |
| Cequr Corporation | $536.81 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $430.12 | 2021-2024 | Omnipod |
| Horizon Therapeutics Plc | $332.90 | 2022-2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $322.29 | 2020-2021 | |
| Dexcom, INC. | $277.96 | 2022-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $247.59 | 2022-2024 | Mounjaro |
| Medtronic, INC. | $235.10 | 2022-2025 | Minimed 780g |
| Mannkind Corporation | $231.68 | 2021-2023 | Afrezza |
| Corcept Therapeutics | $225.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $224.17 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $187.31 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.77 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.79 | 2023 | |
| Alexion Pharmaceuticals, INC. | $92.79 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $53.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garima Narayen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.